Patents Examined by Agnieszka Boesen
  • Patent number: 10400015
    Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: September 3, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Aliaksandr Druz, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, Ulrich Baxa, John Mascola, Rebecca Lynch, Baoshan Zhang, Cheng Cheng
  • Patent number: 10383936
    Abstract: In this study, for the first time, protective efficacy of gD against ILTV challenge was evaluated. Immunization with recombinant Newcastle disease virus expressing ILTV gD induced a higher level of neutralizing antibodies and offered complete protection to chickens against lethal ILTV challenge. Uses of recombinant NDV as a vaccine vector are also described.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: August 20, 2019
    Assignee: University of Maryland, College Park
    Inventors: Siba K. Samal, Mallikarjuna Kanabagatte Basavarajappa, Sweety Samal
  • Patent number: 10376576
    Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: August 13, 2019
    Assignee: ISA Pharmaceuticals B.V.
    Inventors: Wilhelmus Johannes Theodorus Alexander Krebber, Johan Herman Kessler, Cornelis Joseph Maria Melief, Kitty Michelle Corinne Kwappenberg
  • Patent number: 10370731
    Abstract: Methods for the rapid detection of the presence or absence of Hepatitis C Virus (HCV) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting HCV and kits are provided that are designed for the detection of HCV.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: August 6, 2019
    Assignee: ROCHE MOLECULAR SYSTEMS, INC.
    Inventor: Rochak Mehta
  • Patent number: 10363301
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: July 30, 2019
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
  • Patent number: 10357524
    Abstract: A method for treating hepatitis B comprises administering a herbal extract to a subject in need thereof to suppress survival of hepatitis B virus. The herbal extract is manufactured by extracting a herbal composition by a 70-95% aqueous ethanol solution at 40-50° C. The herbal composition comprises 40 wt % of a fruit body sample of Antrodia cinnamomea, 40 wt % of a sample of Polygonatum sibiricum and 20 wt % of a sample of Glycyrrhiza uralensis.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: July 23, 2019
    Assignee: HAN SHENG PHARMTECH, INC.
    Inventors: Shorong-Shii Liou, I-Min Liu, Hung-Tsung Wu
  • Patent number: 10352937
    Abstract: The present invention relates to a pretreatment method of a sample for detecting HBs antigen, which is a surface antigen of the hepatitis B virus, and a method for detecting HBs antigen utilizing the pretreatment method. The present invention also relates to a pretreatment reagent kit for detecting HBs antigen.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: July 16, 2019
    Assignee: SYSMEX CORPORATION
    Inventors: Takahiro Yamagaito, Takuya Koma, Mari Maruki, Kazuhiko Takeda
  • Patent number: 10350289
    Abstract: The present invention relates to a method of vaccinating a patient against varicella zoster virus (VZV) by delivery of an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of a patient's skin at a depth of between about 100 and about 700 microns from the surface of the skin, which is useful for preventing herpes zoster or reducing the severity or duration thereof. In embodiments of the invention, the patient is 50 years of age or older and has been previously exposed to VZV. The invention also relates to a method of preventing VZV infection in an individual who was not previously infected with VZV comprising administering an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of the individual's skin at a depth of between about 100 and about 700 microns from the surface of the skin.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: July 16, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brian K. Meyer, Robert K. Evans, Channing R. Beals, David C. Kaslow
  • Patent number: 10344077
    Abstract: The invention is directed to HIV-1 neutralizing antibodies, CD4 binding site and V3 glycan antibodies, and methods for their uses.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: July 9, 2019
    Assignee: DUKE UNIVERSITY
    Inventors: Barton F. Haynes, Ryan Meyerhoff, M. Anthony Moody, Hua-Xin Liao, Todd Bradley, Mattia Bonsignori
  • Patent number: 10345311
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: July 9, 2019
    Assignee: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • Patent number: 10342862
    Abstract: The invention relates to an immunization regimen whereby an infant is protected against respiratory syncytial virus (RSV) through administration of a first anti-RSV immune response inducing composition to his or her mother during pregnancy, followed by administration of a second anti-RSV immune response inducing composition to the infant after birth.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: July 9, 2019
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventor: Phillip Dormitzer
  • Patent number: 10329584
    Abstract: The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: June 25, 2019
    Assignee: St. Jude Children's Research Hospital
    Inventors: Julia Lea Hurwitz, Toru Takimoto, Charles John Russell, Allen Portner, Karen Slobod
  • Patent number: 10323068
    Abstract: The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: June 18, 2019
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Philippe Gripon, Stephan Urban
  • Patent number: 10300129
    Abstract: The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according in the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: May 28, 2019
    Assignee: HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMB)
    Inventors: Romana Ruiss, Gilbert Reisbach, Wolfgang Hammerschmidt, Reinhard Zeidler
  • Patent number: 10280404
    Abstract: The present invention relates to nucleic acid sequences that encode hepatitis C viruses (HCV) that are useful in the fundamental research of HCV as well as in the search of a vaccine against HCV. In particular the present invention relates to nucleic acid sequences that comprises HCVs which are capable of expressing said virus when transfected into cells and are capable of infectivity in vivo.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: May 7, 2019
    Assignees: Hvidovre Hospital, Københavns Universitet
    Inventors: Jens Bukh, Yiping Li, Santseharay Ramirez Almeida
  • Patent number: 10279020
    Abstract: The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject. The invention provides that a lung cancer cell or other tumor cells, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, and method for stimulating an immune response to a tumor with the tumor cell so genetically modified. The invention additionally provides a method of inhibiting a tumor, including a cancer such as lung cancer, by administering an allogeneic tumor cell, for example a cancer tumor cell such as a lung cancer tumor cell, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: May 7, 2019
    Assignee: University of Miami
    Inventor: Eckhard R. Podack
  • Patent number: 10272149
    Abstract: Vaccine compositions useful for vaccination against a target influenza strain, and method and kits for using the same. The vaccines comprise a live attenuated influenza virus that is synthetically constructed based upon a backbone platform derived from a bat influenza strain, and heterologous surface proteins HA and NA derived from the target influenza strain. The live attenuated virus is non-reassortant with native, circulating influenza strains, and can be used to create vaccines for humans and other animals.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 30, 2019
    Assignees: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION, J. CRAIG VENTER INSTITUTE
    Inventors: David Wentworth, Bin Zhou, Wenjun Ma, Jingjiao Ma
  • Patent number: 10272042
    Abstract: The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic T lymphocyte (CTL) response and methods for their use in the treatment of cancer.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: April 30, 2019
    Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Pirouz M. Daftarian, Marc Mansour, Bill Pohajdak, Robert G. Brown, Wijbe M. Kast
  • Patent number: 10258684
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: April 16, 2019
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • Patent number: 10251936
    Abstract: The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: April 9, 2019
    Assignee: The Catholic Unviersity of Korea Industry-Academic Cooperation Foundation
    Inventors: Tai Gyu Kim, Hyun Il Cho